NSCLC

This study tests whether adding the drug BIO 300 to standard chest radiation can prevent severe lung inflammation (pneumonitis) in people with early-stage non-small cell lung cancer who also have interstitial lung disease (lung scarring). About 25 participants will receive both t…

This study tests a new drug called EIK1001 combined with standard treatments (pembrolizumab and chemotherapy) in 70 people with stage 4 non-small cell lung cancer who haven't had prior treatment. The goal is to see if the combination is safe and shrinks tumors. Participants must …

This study tests a new drug called HC010 in 50 people with advanced non-small cell lung cancer that has a specific marker (PD-L1). The goal is to see if the drug can shrink tumors and how safe it is. Participants receive the drug as their first treatment, and researchers monitor …

This study is for people with stage III non-small cell lung cancer that cannot be removed by surgery. It tests whether adding another immunotherapy drug (tremelimumab) and extra chemotherapy to the standard treatment (durvalumab) can lower the amount of cancer DNA found in the bl…

This early-phase study tests a new drug called SLV-154 in about 70 adults with advanced solid tumors that have spread (including head and neck, lung, breast, and other cancers). The main goal is to find the safest dose and check for side effects. Researchers will also watch for a…

This study is for people with locally advanced non-small cell lung cancer who haven't had treatment yet. It tests a combination of two immunotherapy drugs (cemiplimab and fianlimab) given before and during standard radiation therapy, without chemotherapy. The goal is to see if th…

This study tests whether adding targeted radiation to liver tumors can make standard immunotherapy work better for people with stage IV non-small cell lung cancer that has spread to the liver. About 68 adults will receive either standard drug therapy alone or standard therapy plu…

This study tests an experimental oral drug, S241656, in people with advanced cancers that have certain gene changes (KRAS, BRAF, or related mutations). The drug is given alone or with other cancer treatments. The goal is to find safe doses and see if the drug shrinks tumors. Abou…

This study looks at two types of radiation for people with 4 to 15 brain tumors that have spread from other cancers. One is a precise, short treatment called CyberKnife, and the other is whole-brain radiation given over 10 sessions. The goal is to see which approach helps patient…

This study tests a new type of CAR T cell therapy for adults with advanced solid tumors, including colorectal, pancreatic, lung, ovarian, and mesothelioma cancers. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells that have lost a specif…

This early-phase study tests a new drug called PRTH-101, alone or with pembrolizumab, in adults with advanced or metastatic solid tumors (like lung cancer). The main goals are to check safety, find the best dose, and see how the drug works in the body. About 270 participants will…

This study tests whether combining a targeted drug (adagrasib) with precise radiation (SRS) can control brain metastases in people with a specific type of lung cancer (KRAS G12C-mutated NSCLC). About 30 adults with untreated brain tumors will receive both treatments. The goal is …

This early-phase study tests a new drug called BBO-11818 in people with advanced solid tumors (lung, pancreatic, colorectal, or others) that have a specific KRAS gene mutation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Abo…

This study tests whether adding a local treatment (like radiation or surgery) to the targeted therapy brigatinib can better control advanced ALK-positive lung cancer. About 45 adults whose cancer has shrunk or stabilized on brigatinib alone will receive the extra treatment. The g…

This study tests whether adding two immune-boosting drugs (iparomlimab and tuvonralimab) to standard chemotherapy can shrink tumors in people with stage III lung cancer that cannot be surgically removed. About 33 adults aged 18–75 who have not had prior treatment for their cancer…

This study tests a new drug called EP0031 in people with advanced cancers that have a specific genetic change (RET alteration). The goal is to see if the drug is safe and can shrink tumors. About 265 adults with non-small cell lung cancer or other solid tumors will take part.

This study tests whether adding an experimental vaccine (OSE2101) to an immunotherapy drug (cemiplimab) can better clear cancer DNA from the blood of people with advanced non-small cell lung cancer. The trial enrolls 160 adults whose cancer has not worsened after initial chemo-im…

This study is for people with advanced non-small cell lung cancer (stage IIIB/C-IV) who cannot tolerate standard chemoradiation. It tests a treatment plan of chemotherapy followed by targeted radiation and an immunotherapy drug called Tislelizumab. The goal is to see if this comb…

This early-phase trial tests an experimental oral drug, NST-628, in adults with advanced solid tumors that have specific genetic changes in the MAPK pathway and have stopped responding to standard treatments. The study aims to find a safe dose and check for early signs of tumor s…

This study looks at people with lung cancer that has spread to the brain but causes few or no symptoms. It compares taking the drug alectinib alone versus alectinib plus targeted brain radiation. The goal is to see if delaying radiation keeps the brain cancer under control and av…

This study tests a new pill, RMC-6236, against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific change in the RAS gene. About 420 adults who have already tried at least one prior treatment will be randomly assigned to receiv…

This study tests a new drug, STX-721, in people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2 exon 20 insertions). The goal is to find a safe dose and see if the drug can shrink tumors. About 251 participants will take the drug by mouth,…

This early-stage study tests a new drug called TORL-1-23 in people with advanced solid tumors (ovarian, endometrial, or lung cancer). The main goals are to check safety, find the best dose, and see if it can shrink tumors. About 90 participants will receive the drug in increasing…

This early-phase study tests a new treatment called NK510 (a type of immune cell therapy) combined with PD-1 inhibitors for people with advanced non-small cell lung cancer that has come back or not responded to prior treatments. The trial includes two ways to give the therapy: th…

This study tests a drug called repotrectinib in people with a specific type of lung cancer (ROS1-positive non-small cell lung cancer) that has spread to the brain. The goal is to see if the drug can shrink or control brain tumors. About 20 adults will take the drug by mouth, and …

This study tests whether using a tool called OncoChoice to pick chemotherapy drugs can improve tumor shrinkage in people with advanced non-small cell lung cancer (NSCLC) that has spread. About 29 adults who have already tried at least one prior treatment will receive standard che…

This study tests a new drug called JAB-8263 in adults with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 152 people will take part in this early-phase tr…

This study tests whether adding a drug called narlumosbart and precise radiation (SBRT) to standard chemotherapy and immunotherapy can help people with advanced lung cancer that has spread to the bones. The drug and radiation are meant to improve the immune system's ability to fi…

This study tests a new drug called HLX37 in people with advanced or metastatic solid tumors (cancers that have spread). The drug is a bispecific antibody that targets two proteins (PD-L1 and VEGF) involved in tumor growth. The main goals are to check the drug's safety, find the r…

This study tests a new combination of drugs (RAS(ON) inhibitors plus ivonescimab) in adults with advanced or metastatic solid tumors that have a RAS mutation. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 370 people with cancers l…

This study tests a new drug called TNG462, given with other cancer medicines, for people with pancreatic or lung cancer that has a specific genetic change (MTAP loss). The goal is to find safe doses and see if the combination shrinks tumors. About 183 adults with advanced cancer …

This study tests an experimental oral drug called Alintegimod combined with standard immunotherapies (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, or liver cancer who have already tried other treatments. The goal is to see if the com…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced or spreading solid tumors that have a specific change in the TP53 gene (Y220C mutation). The goal is to see if the drug is safe and works against these cancers. About 300 adults (and some teens after …

This study is for adults aged 70 or older, or those who are frail, with advanced non-small cell lung cancer that has a low PD-L1 score. The goal is to see if using a reduced dose of chemotherapy together with an immunotherapy drug (anti-PD-1) causes fewer side effects that force …

This early-phase study tests a new drug, enzelkitug, alone or with standard immunotherapy, in adults with advanced solid tumors (e.g., lung, melanoma, breast, colon). The main goals are to check safety, find the right dose, and see if it shrinks tumors. About 450 participants wil…

This early-phase trial tests a new drug, TUB-030, in adults with advanced solid tumors like head and neck, lung, breast, or colorectal cancer. The main goals are to find a safe dose and check for side effects. Researchers will also compare different doses in people with head and …

This study tests an experimental drug called YL202 in about 200 people with advanced solid tumors, including lung, breast, and head & neck cancers. The goal is to see if the drug can shrink tumors and how safe it is. Participants must be between 18 and 75 years old and have tried…

This study is for people with advanced solid tumors like melanoma, lung cancer, or liver cancer. It tests whether adding metformin or rosiglitazone (drugs that change how cells use energy) to standard immunotherapy (anti-PD-1) can improve treatment response. Participants will hav…

This early-phase study tests a new drug called IDE161, alone or with another drug (pembrolizumab), in people with advanced solid tumors (like breast, ovarian, prostate, or lung cancer) that have not responded to other treatments. The main goals are to check safety, find the right…

This study looks at how well a drug called sugemalimab works when combined with standard chemotherapy as the first treatment for people with advanced non-small cell lung cancer (NSCLC). The study is happening in real-world clinics, not just research hospitals, and includes 150 ad…

This early-stage study tests a new drug called RMC-5127 in adults with advanced solid tumors that have a specific KRAS G12V gene change. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 574 people with lung, colorectal, or panc…

This early-phase study tests a new drug (ORIC-114) combined with an existing targeted therapy (amivantamab) in about 76 people with advanced lung cancer that has a specific genetic change (EGFR exon20 insertion). The goal is to find the safest dose and see if the combination can …

This study tests whether adding the drug MK-2870 to standard pembrolizumab after initial chemo-immunotherapy helps people with advanced squamous non-small cell lung cancer live longer. About 851 participants will receive pembrolizumab plus chemotherapy, then either continue pembr…

This study compares two treatments given before surgery for stage II-IIIA non-small cell lung cancer: immunotherapy (toripalimab) plus radiation versus immunotherapy plus chemotherapy. The goal is to see which combination works better at shrinking tumors and improving surgery out…

This study tests whether adding the drug sintilimab to standard chemotherapy and a personalized radiation plan can help control stage III non-small cell lung cancer. About 35 adults aged 18-75 who cannot have surgery will receive the combination. The main goal is to see how long …

This study tests a new treatment for people with a certain type of lung cancer (stage II to IIIB) who had surgery but still had cancer cells left after standard chemo and immunotherapy. The treatment combines a special immune cell therapy (L-TIL) with another immunotherapy drug (…

This study tests whether adding a special surgical glue (Progel Platinum) to the standard stapling method during lung cancer surgery can help patients recover faster. About 160 adults having keyhole surgery for non-small cell lung cancer will take part. The main goal is to see if…

This early-phase study tests a new drug called OKN4395, alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. About 166…

This early-phase study tests a new drug called NRM-823, alone or with an immunotherapy, in 150 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. The study includes several cancer types lik…

This study is for people with a common type of advanced lung cancer (non-small cell) that has stopped responding to current targeted pills. The trial will test a two-step approach: first, standard chemotherapy, then a newer targeted drug called befotertinib. The goal is to see if…

This early-phase study tests a new drug called ONO-7428 in about 60 adults with advanced solid tumors (including some lung cancers) that have not responded to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the right dose. Participants …

This study tests a new treatment called T3011, given as a shot directly into tumors, for people with advanced or metastatic solid tumors (like melanoma or lung cancer). It is for adults whose cancer has worsened after standard treatments. The goal is to see if T3011 is safe and c…

This study tests a new drug that delivers radiation directly to cancer cells with a specific marker (GRPR). It is for adults with advanced cancers like prostate, breast, lung, or colon cancer that have come back or spread. The main goal is to find a safe dose and check for side e…

This study tests a new drug called REGN5093 in people with advanced non-small cell lung cancer that has a specific change in the MET gene. The goal is to find a safe dose and see if the drug can shrink tumors. About 231 participants will take part in two phases: first to check sa…

This study tests an experimental drug called VT3989, taken daily by mouth, in people with advanced solid tumors, mesothelioma, or non-small cell lung cancer that has stopped responding to standard treatments. The main goals are to check the drug's safety and side effects, and to …

This early-stage study tests a new drug called BBO-8520 in about 350 adults with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The main goals are to check safety and find the right dose, while also seeing if the drug shrinks tumors. Participa…

This study is testing a new blood test called TheraSure CNI-Monitor for people with advanced lung cancer (NSCLC) who are receiving immunotherapy. The test looks for tiny bits of tumor DNA in the blood to see if the cancer is responding to treatment. Researchers want to know if th…

This study tests whether using CPAP or BiPAP breathing machines during radiation therapy can reduce tumor movement in people with advanced lung cancer, esophageal cancer, or lymphoma. About 31 participants will try both types of ventilation to see which one increases lung volume …

This study compares a new radiation technique called lattice radiation therapy (LRT) to standard stereotactic body radiation therapy (SBRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better and helps immune cells attack…

This study looks at whether a special intermittent fasting diet can help people with advanced lung cancer who are receiving immunotherapy. Researchers want to see if the diet is safe and if it can make the cancer treatment work better. About 66 patients will take part, following …

This study is for people with certain advanced cancers (like lung, head and neck, or esophageal cancer) who are already receiving immunotherapy. Researchers want to see if adding radiation therapy improves outcomes and, more importantly, if changes in immune cells in the blood ca…

This study is gathering tumor tissue and blood cells from 200 adults with advanced solid tumors like colorectal, lung, or pancreatic cancer. The goal is to learn how often certain genetic changes occur and to store participants' own immune cells for possible future use in making …

This study looks at how the immune system reacts to immunotherapy in people with non-small cell lung cancer (NSCLC). Researchers will collect blood samples from 270 participants to detect antibodies that may affect treatment. The goal is to better understand why some patients res…

This study observes adults with metastatic non-small cell lung cancer who have certain EGFR gene changes and are already receiving amivantamab plus chemotherapy through an early access program. Researchers will collect medical data to see how long the cancer stays under control a…

This study is testing whether a computer model can predict how well a combination of chemotherapy and immunotherapy works before surgery for people with non-small cell lung cancer. Researchers will collect data from 500 participants to build and test the model. The goal is to hel…

This study looks at whether chest CT scans can help predict how well lung cancer responds to chemoimmunotherapy given before surgery. Researchers will compare CT images taken before and after treatment with actual tumor samples from surgery. The goal is to develop a non-invasive …

This study looks at people with early-stage lung cancer who had surgery and have no detectable tumor DNA in their blood. Half will get standard follow-up care, and the other half will have regular DNA tests and imaging instead of immediate extra treatment. The goal is to see if t…

This study is testing whether a special PET scan can predict how well a targeted cancer drug works in people with advanced lung cancer. About 50 adults with metastatic non-small cell lung cancer will get the scan before and during treatment. The goal is to see if changes in the s…

This study aims to uncover the molecular differences between the original lung tumor and cancer that has spread to other parts of the body. Researchers will analyze DNA from stored tumor samples of 25 adults with non-small cell lung cancer who are healthy enough for surgery. The …